Welcome to our dedicated page for Impact Biomedical SEC filings (Ticker: IBO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Impact BioMedical Inc. (IBO), a Nevada-incorporated biotechnology company listed on the NYSE American. These regulatory documents offer detailed insight into the company’s governance, capital structure, and strategic transactions, and are a key resource for investors analyzing IBO.
Impact BioMedical’s annual and quarterly reports, such as its Form 10-K referenced in proxy materials, describe the company’s business model of discovering, confirming, and patenting technologies for biopharmaceutical and consumer healthcare and wellness applications. These filings typically discuss the company’s technology platforms, risk factors, and financial condition in more depth than press releases.
The company’s definitive proxy statements (DEF 14A) provide information on corporate governance, director and executive officer roles, board committees, executive compensation, and stockholder voting procedures. For example, the 2025 proxy statement outlines the agenda for the annual meeting, including director elections, ratification of the independent registered public accounting firm, and an advisory vote on executive compensation, as well as details about majority ownership by DSS BioHealth Securities, Inc.
Current reports on Form 8-K are especially important for tracking material events at Impact BioMedical. Recent 8-K filings describe the entry into a Merger and Share Exchange Agreement with Dr Ashleys entities and a newly formed PubCo, including the planned structure under which Impact BioMedical and Dr Ashleys would become wholly owned subsidiaries of PubCo. Other 8-Ks report on matters such as the conversion of Series A Convertible Preferred Stock into common stock and the results of the 2025 annual meeting of stockholders.
Through this filings page, users can also review information relevant to capital structure and ownership, including voting arrangements, preferred stock designations, and support agreements related to the planned merger. Insider ownership and changes in control are discussed in proxy statements and referenced SEC reports.
Stock Titan’s platform surfaces these filings as they are posted to EDGAR and can pair them with AI-powered summaries to help explain complex sections, such as merger terms, voting requirements, or compensation disclosures. Investors interested in Impact BioMedical’s strategic merger, governance practices, or equity structure can use this page to locate the underlying documents, including 10-Ks, 10-Qs, 8-Ks, and DEF 14A filings, and rely on AI-generated highlights to quickly understand the key points.
IMPACT BIOMEDICAL INC. Chief Financial Officer Todd D. Macko reported open-market sales of 45,000 shares of Common Stock. The transactions occurred on March 25 and March 27, 2026 at prices around $0.60 per share. After these sales, he directly holds 155,122 shares of Common Stock.
IMPACT BIOMEDICAL INC. director Jason Grady reported an open-market sale of 50,000 shares of common stock at an average price of $0.6501 per share. After the transaction, he directly holds 250,182 common shares, indicating he retains a substantial ongoing equity stake in the company.
Impact Biomedical Inc. reported a net loss of $11,870,000 for the year ended December 31, 2025, as it continues to invest in biotech and consumer wellness technologies without yet generating meaningful revenue. The company recorded $32,000 of Celios air purification retail sales against total costs and expenses of $4,314,000, plus a $9,388,000 fair value loss on a related-party note.
During 2025 it expanded its intellectual property to sixty-nine issued patents and more than sixty pending patents, advanced platforms such as Linebacker, Laetose, 3F and Equivir, and acquired Celios air purification technology. It also agreed to a reverse merger with Dr. Ashleys Limited and converted about $15,000,000 of DSS debt into 31,939,778 common shares, eliminating all non‑trade debt. Despite these steps, the company’s history of losses and negative operating cash flow led management to disclose substantial doubt about its ability to continue as a going concern. As of June 30, 2025, non‑affiliate common stock held had a market value of $7,599,000, and as of March 6, 2026 there were 107,821,231 common shares outstanding.
Impact BioMedical Inc. amended its merger, voting, and transition agreements tied to its planned business combination with Dr Ashleys. PubCo will issue 22,000 compensation shares to Impact’s CEO and up to 128,000 ordinary shares to DSS, Inc., all deducted from the Company Share Consideration.
The amended definition provides for 169,560,000 PubCo ordinary shares as Company Share Consideration, representing 94.20% of PubCo’s outstanding shares at Closing, before compensation and DSS shares. The merger End Date was extended from March 31, 2026 to July 1, 2026, and supporting stockholders now collectively hold 92,980,843 Impact shares, or about 88.87% on a fully diluted basis.
DSS, Inc. agreed to funding and hold harmless obligations and to support Impact’s co-signing of certain loan agreements, in return for the DSS share grants, which are intended to be fully paid, non-assessable, registered, and freely tradable under the Securities Act, subject to an effective registration statement.
Impact Biomedical Inc. reported insider share sales by a reporting entity that is a wholly owned subsidiary of DSS, Inc. The insider sold 115,600 shares of common stock on 05/22/2025 at an average price of $0.5491 per share and 45,400 shares on 05/27/2025 at an average price of $0.5403 per share, both coded as sales. After these transactions, the reporting person beneficially owns 545,024 shares of Impact Biomedical common stock, held directly.
The filing is an amendment that corrects a previous error in the number of Impact Biomedical shares that DSS, Inc. beneficially owns. The corrected figure includes 545,024 shares received in connection with the Celios asset sale.
Impact BioMedical Inc. obtained stockholder approval by written consent to give its Board discretion to carry out a reverse stock split of its common stock. The split ratio may be set at not less than 1-for-12.48 and not more than 1-for-50, at any time on or before December 30, 2026, as determined by the Chief Executive Officer. As of the December 22, 2025 record date, the company had 104,621,231 common shares outstanding, and holders of 93,076,622 votes (about 89% of voting power), led by DSS, Inc., approved the action. The company explains that the reverse split is intended to raise its share price, support continued listing on the NYSE American, and potentially broaden investor interest, while warning that it may not achieve these goals and could reduce liquidity and increase odd-lot holdings. The number of authorized shares will remain 4,000,000,000, so available but unissued shares will increase after any split, which the Board notes could have potential anti-takeover and dilutive effects.
Impact BioMedical, Inc. (IBO) filed its Q3 2025 10‑Q showing continued operating losses and a going concern warning. The company reported total revenue of $18,000 for the quarter, driven by initial Celios air purification retail sales, and an operating loss of $948,000. Net loss was $1,475,000 for the quarter and $17,105,000 year‑to‑date.
Cash and cash equivalents were $12,000 at September 30, 2025, with net cash used in operating activities of $1,989,000 for the nine months. Current liabilities totaled $23,793,000, including a related‑party note payable measured at $22,881,000, contributing to a total liabilities balance of $27,061,000 and a stockholders’ equity deficit of $8,853,000.
The quarter included amortization expense tied to $17,278,000 of net intangible assets and the first Celios sales after acquiring DSS PureAir assets in February 2025. Subsequent to quarter‑end, 60,496,041 preferred shares converted to common and the related‑party note was converted into 31,939,778 common shares; as of October 27, 2025, common shares outstanding were 104,621,231.
Impact Biomedical Inc. (IBO) reported results of its 2025 annual meeting of stockholders. A quorum of 64,328,010 shares, representing 88.50% of shares outstanding and eligible to vote as of September 8, 2025, was present in person or by proxy.
Stockholders elected eight directors—Frank D. Heuszel, Elise Brownell, Melissa Sims, Castel(l) Hibbert, David Keene, Christian Zimmerman, Jason Grady, and Chan Heng Fai Ambrose—to serve until the next annual meeting. They also ratified Grassi & Co. Certified Public Accountants, P.C. as independent auditor for fiscal year 2025 with votes 64,126,924 for, 174,317 against, and 26,769 abstain. On an advisory basis, stockholders approved executive compensation with 61,512,770 for, 107,684 against, 4,795 abstain, and 2,702,761 broker non‑votes.
Impact BioMedical Inc. announced the conversion of its Series A Convertible Preferred Stock into common stock under Section 6 of the Certificate of Designation dated October 30, 2023. The holder, DSS BioHealth Security, Inc., elected the Optional Conversion permitted seventy-five days after issuance.
Following this election, DSS BioHealth Security, Inc. is deemed the record holder of 60,496,041 shares of the Company’s common stock, $0.001 par value per share. The event was reported as of October 24, 2025.
Impact Biomedical Inc. proxy content lists company leadership, director cash compensation and limited executive compensation details. The document shows Frank D. Heuszel as Chief Executive Officer and Executive Chairman and includes other officers and directors: Mark Suseck (Chief Operating Officer), Todd D. Macko (Chief Financial Officer), Elise Brownell, Melissa Sims, Chris(tian) Zimmerman, David Keene, Castel Hibbert, Chang Heng Fai Ambrose and Jason Grady. Director cash retainers appear as $1,250 and meeting fees $925, totaling $2,175 for several directors. Reported 2024 compensation items include $126,689 and $32,000 for Mark Suseck (total $158,689) and $555 for Todd D. Macko in 2024. An aggregate ownership line lists 95,779 shares for all officers and directors as a group and notes holdings as <1% for certain entries.